1 | 77 | Clear cell endometrial carcinoma | mut. L755S ERBB2 | Evaluable for Afatinib |
2 | 67 | High grade serous ovarian carcinoma | Mut. V600E BRAF | Ongoing Dabrafenib + trametinib |
3 | 54 | Squamous cervical carcinoma | HPV at ISH | Ongoing Atezolizumab + anti ICOS |
4 | 52 | Endometrial carcinosarcoma | MSI | Evaluable for Atezolizumab |
5 | 71 | Endometrial carcinoma | Mut R88Q PI3KCA | Evaluable for Everolimus + exemestane |
6 | 30 | Mucinous cervical adenocarcinoma | splice site (134+1G>T) PTEN | Evaluable for Everolimus |
7 | 60 | Low grade serous ovarian carcinoma | Mut. V600E BRAF | Ongoing Trametinib |
8 | 41 | Squamous cervical carcinoma | Mut p.E545K PI3KCA | Ongoing Alpelisib |
9 | 71 | Endometrioid Endometrial carcinoma | Mut. Q546P PI3KCA | Evaluable for Alpelisib |
10 | 39 | Neuroendocrine cervical cancer | Mut p.E545K PI3KCA | Ongoing Alpelisib |